Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 12, 2008. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 4,580,000 Ordinary shares of 25 pence each.
- Purchase Date: February 11, 2008.
- Purchase Price: 1,090.1962 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.16% of total voting rights).
- Shares in Issue: 5,506,313,683 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 4,580,000 repurchased shares. Consequently, the Company's Treasury shareholding now represents 9.16% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying 4,580,000 shares by the price of 1,090.1962 pence.
- Confirm the updated total voting rights denominator (5,506,313,683 shares) for compliance with disclosure thresholds.
- Review the impact of the 9.16% Treasury shareholding on future earnings per share calculations.
- Check subsequent filings for the utilization of remaining share buyback authority granted in May 2007.